Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.46 |
| ▸ | ACE | P12821 | 5/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894761 | 0.92 | OPRD1 (0.42) | MMEACECPA1ACE2OPRM1 | |
| SCHEMBL30123072 | 0.92 | OPRD1 (0.44) | MMEOPRM1OPRD1 | |
| SCHEMBL29895454 | 0.92 | ENPEP (0.43) | MMEACECPA1ACE2OPRM1 | |
| SCHEMBL30116291 | 0.89 | MME (0.38) | MMEACE | |
| SCHEMBL29384990 | 0.87 | ACE (0.38) | MMEACE | |
| SCHEMBL29531471 | 0.86 | ACE (0.47) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL31256968 | 0.86 | OPRD1 (0.46) | MMEACEOPRM1OPRD1 | |
| SCHEMBL29615620 | 0.85 | ACE (0.48) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL29961809 | 0.85 | MME (0.45) | MMEACECPA1ACE2 | |
| SCHEMBL31274737 | 0.84 | MME (0.50) | MMEACEOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2023-07-06 | — | — | US | claimed |
| EP-4076533-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2022-10-26 | — | — | EP | claimed |
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2023-07-06 | — | — | US | disclosed |
| EP-4076533-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | AGL, PGLS, DDOST | MME 3931/4885ACE 3445/4885CPA1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.